Since the landmark discovery of the Philadelphia chromosome and its oncogenic product BCR-ABL in chronic myeloid leukaemia (CML), numerous other chromosomal rearrangements have been identified across different human cancers. Historically, chromosomal rearrangements have been more commonly studied in haematological rather than epithelial malignancies, in part because of the greater ease of tissue accessibility and cytogenetic analyses. However, in the past three decades the number of recurrent chromosomal rearrangements identified in common epithelial cancers has increased. Of particular interest are those rearrangements that lead to the expression of oncogenic and potentially 'druggable' fusion kinases. The first fusion kinases that were discovered in solid tumours involved the RET and neuro trophic tyrosine kinase receptor type 1 (NTRK1) genes in thyroid cancer 1 . In 2002, the fusion of ETS variant 6 (ETV6; also known as TEL) with NTRK3 was identified in secretory breast carcinoma, which is a rare subtype of breast cancer 2 . Anaplastic lymphoma kinase (ALK) and ROS1 fusions have more recently been found in non-small-cell lung cancer (NSCLC) and other epithelial cancers 3,4 . Although these cancers may have different kinase fusions, they share the common biological feature of 'oncogene addiction' -an increased dependency on the activated kinase for cellular proliferation and survival 5 .
Since the landmark discovery of the Philadelphia chromosome and its oncogenic product BCR-ABL in chronic myeloid leukaemia (CML), numerous other chromosomal rearrangements have been identified across different human cancers. Historically, chromosomal rearrangements have been more commonly studied in haematological rather than epithelial malignancies, in part because of the greater ease of tissue accessibility and cytogenetic analyses. However, in the past three decades the number of recurrent chromosomal rearrangements identified in common epithelial cancers has increased. Of particular interest are those rearrangements that lead to the expression of oncogenic and potentially 'druggable' fusion kinases. The first fusion kinases that were discovered in solid tumours involved the RET and neuro trophic tyrosine kinase receptor type 1 (NTRK1) genes in thyroid cancer 1 . In 2002, the fusion of ETS variant 6 (ETV6; also known as TEL) with NTRK3 was identified in secretory breast carcinoma, which is a rare subtype of breast cancer 2 . Anaplastic lymphoma kinase (ALK) and ROS1 fusions have more recently been found in non-small-cell lung cancer (NSCLC) and other epithelial cancers 3, 4 . Although these cancers may have different kinase fusions, they share the common biological feature of 'oncogene addiction' -an increased dependency on the activated kinase for cellular proliferation and survival 5 . As a result, these cancers are often highly susceptible to small-molecule kinase inhibitors, several of which have advanced rapidly in the clinic. The discovery and successful targeting of oncogenic fusion kinases have helped to drive a major paradigm shift in oncology, whereby somatic genetic alterations -rather than the histological subtype -provide the basis for the selection of therapies.
In this Review, we focus on chromosomal rearrangements that lead to the activation of tyrosine kinases in epithelial cancers. We first discuss cellular and molecular mechanisms that may lead to chromosomal rearrangements in cancer. Then, we assess how chromosomal rearrangements can activate tyrosine kinases, how this activation leads to a state of oncogene addiction, and how the discovery of these processes has led to new diagnostic and therapeutic opportunities in the clinic. Although this Review focuses on tyrosine kinase fusions, other kinase fusions are becoming potential drug targets (BOX 1) and might follow a similar route of development from discovery to clinical validation.
Epidemiology and aetiology
Among unselected epithelial tumours, the overall rate of balanced rearrangements, which is defined as the even exchange of genetic material with no loss or duplication of DNA, has been estimated to be only 3%, whereas it is 19% in mesenchymal tumours and 29% in acute myelogenous leukaemia (AML) 6 . However, among cancers with an abnormal karyotype, the frequency of rearrangements is surprisingly similar; for example, chromosomal rearrangements that involve transcriptional regulators occur in 38% of haematological malignancies and in 44% of solid tumours that have abnormal karyotypes. Likewise, tyrosine kinase fusion genes have been identified in a similar proportion (5-7%) of haematological, mesenchymal and epithelial tumours that have abnormal karyotypes 6 . Although the fraction of epithelial tumours that have an abnormal karyotype is smaller than that of haematological malignancies, these observations suggest that gene fusion events occur across all types of cancer, including a small but important fraction of epithelial cancers.
To date, ten different tyrosine kinases have been identified as fusion kinases in various different epithelial tumours (TABLE 1) . Gene fusions that involve most of these tyrosine kinases have also been identified in non-epithelial tumours and implicated in their pathogenesis. The incidence of tyrosine kinase fusions widely varies depending on the kinase and the tumour type; for example, fusions of RET have been reported in more than one-third of papillary thyroid cancers in the United States 7 , but they are found in only 1% of NSCLCs 8, 9 . ROS1 fusions are similarly rare in NSCLC 8, 10 , but rearrangements that involve the related receptor tyrosine kinase anaplastic lymphoma kinase (ALK) are more common: they occur in 3-7% of NSCLCs 8, 11 . On the basis of an estimated 1.3 million new cases of NSCLC worldwide per year 12 , small percentages of tyrosine kinase fusion incidence translate into relatively large numbers of patients. For example, more than 50,000 people worldwide who are diagnosed with NSCLC every year probably have an ALK rearrangement. This is similar to the total number of new cases of CML per year 13, 14 .
Environmental causes of gene rearrangements. The causal link between exposure to ionizing radiation and gene fusion events in cancer is well established, particularly for papillary thyroid cancer. Radiation has long been known to increase the probability of childhood thyroid cancer, and a large increase in childhood papillary thyroid cancer occurred in areas surrounding Chernobyl 15, 16 . Consistent with in vitro studies showing that irradiation induces RET translocations 17, 18 , RET gene rearrangements have been reported in more than 60% of individuals who developed papillary thyroid carcinomas after the Chernobyl nuclear accident [19] [20] [21] [22] [23] [24] . NTRK1 and BRAF rearrangements have also been found in papillary thyroid cancers of patients after the Chernobyl nuclear accident, but they are much less common than RET rearrangements 21, 25 . Recently, ALK rearrangements have been reported in radiationassociated papillary thyroid carcinoma but not in sporadic cases where patients have not been exposed to increased levels of radiation 26 . For other epithelial cancers, no definite link between radiation exposure and gene fusion events has been established. There are clear links between radiation exposure and the development of certain cancers [27] [28] [29] [30] ; for example, epidemiological studies have linked radon exposure to lung cancer. However, the potential involvement of radon in chromosomal rearrangements has only been shown in preclinical models [31] [32] [33] . It is not known whether these or other radiation-associated tumours in patients are enriched in recurrent chromosomal rearrangements.
Key points
• Chromosomal rearrangements that lead to oncogenic kinase activation are an emerging paradigm in epithelial cancers.
• Ten different tyrosine kinases have currently been identified as fusion kinases in various different epithelial tumours. Tyrosine kinase gene rearrangements generally define molecularly distinct subsets of patients.
• Cancers that harbour tyrosine kinase gene rearrangements express activated fusion kinases that drive the initiation and progression of malignancy. These cancers become dependent on (or 'addicted' to) continued signalling from the oncogenic fusion kinase.
• Several tyrosine kinase inhibitors have been shown to be active in cancers that harbour specific tyrosine kinase fusions, which validates these fusion kinases as bona fide targets. In the case of anaplastic lymphoma kinase (ALK)-rearranged lung cancers, ALK inhibitors like crizotinib have become a standard therapy.
• Multiplexed genetic analyses that include screening for tyrosine kinase fusions will help to accelerate the process of target discovery and clinical validation.
Box 1 | Serine/threonine kinase rearrangements in carcinomas
Recurrent rearrangements of serine/threonine kinases, most notably RAF and microtubule-associated serine/threonine (MAST) family kinases, have recently been identified in thyroid, prostate, gastric and breast carcinomas 25, 124, 125 . In particular, fusions that involve the RAF family of kinases are of considerable interest because of the recent successful development of potent RAF and MEK inhibitors in melanomas that harbour BRAF V600E mutations. BRAF fusions were initially identified in thyroid cancer in 2005 (REF. 25 ). A-kinase anchor protein 9 (AKAP9)-BRAF fusions were found in 11% of thyroid tumours that develop soon after radiation exposure. Of note, the fusions were absent in radiation-induced late-onset tumours, present in only 1% of sporadic tumours and were mutually exclusive with BRAF mutations. RAF family rearrangements were subsequently identified in prostate and gastric cancers 124 . Gene fusions that involve ETS family transcription factors are common in prostate cancer, although they are not currently 'druggable'. However, by screening ETS rearrangement-negative prostate cancers, Palanisamy et al. 124 identified solute carrier family 45, member 3 (SLC45A3)-BRAF and epithelial splicing regulatory protein 1 (ESRP1)-RAF1 fusions. In the study by Palanisamy et al., the examination of 349 prostate cancer specimens showed six specimens with rearrangements that involved BRAF and four specimens with rearrangements of RAF1. Expression of these gene fusions resulted in the transformation of prostate cells and caused those cells to become sensitive to RAF inhibitors. By expanding the scope of their screening to include other carcinomas, the authors found a similar incidence of BRAF gene fusions in gastric cancer (2 out of 105). Again, those tumours that harboured the BRAF fusions did not contain the BRAF V600E mutation. Several generations of RAF and MEK inhibitors have been developed and are in various stages of clinical development 126 . The RAF inhibitors vemurafenib and dabrafenib, and the MEK inhibitor trametinib, have shown clinical activity against melanomas that harbour BRAF V600E mutations. However, it remains to be determined whether these inhibitors will have clinical efficacy against cancers that harbour RAF fusions. Several other risk factors for gene fusion events in epithelial cancers have been studied. DNA topoisomerase relaxes supercoiled DNA by cleaving and re-ligating doublestranded DNA. Topoisomerase poisons, including mitoxantrone, etoposide and doxorubicin, that are used to treat patients with cancer can lead to balanced rearrangements and to leukaemias, although there is little evidence to suggest that the rates of secondary non-haematological malignancies are increased 34 . It has also been suggested that oxidative stress contributes to chromosomal instability 35 . However, it is thought that cigarette smoking -the major risk factor for the develop ment of lung cancerdoes not cause a predisposition to lung cancers that are driven by tyrosine kinase fusions, because most of these cancers develop in patients who have never smoked or have a minimal history of smoking 8-10, [36] [37] [38] . Interestingly, certain gene fusion events occur at a younger age; for example, multiple case series have shown that patients with lung cancers that have ALK, ROS1 or RET translocations are significantly younger than patients with lung cancer who do not have these gene rearrangements 8-10, [36] [37] [38] [39] . Similarly, an association between RET rearrangements and younger age has also been reported in studies of papillary thyroid cancer 7 , which include both radiation-and Ranges from 3% to 85% across studies. § For these fusions, the 5ʹ fusion partner is the tyrosine kinase gene. 
non-radiation-associated cases 40 . In the case of radiationinduced RET rearrangements, the increased susceptibility of children compared to adults has been attributed to more rapid thyroid cell proliferation 41 . At the molecular level, the precise mechanisms that underlie the development of chromosomal rearrangements have yet to be elucidated. The identification of recurrent rearrangements across a broad range of tumour types suggests the presence of common or shared molecular mechanisms that are not dependent on the kinase or the cell type. Primarily on the basis of studies in nonepithelial cells and cancers, it is likely that several steps are required: the generation of double-strand breaks (DSBs) [42] [43] [44] [45] [46] [47] , juxtaposition and aberrant joining of the DNA ends [48] [49] [50] , and selection for gene rearrangements that confer a growth or survival advantage (FIG. 1a) . As the first two steps have recently been reviewed 51 , we primarily focus our discussion on the third step.
Selection for oncogenic chromosomal translocations. For a long time, it was thought that the generation of DNA DSBs was random and that differential selection led to signature translocations. However, it is now appreciated that different tissues and cell types have nuclear dynamics and Second, the ends of the broken DNA have to be brought into close proximity. This juxtaposition can occur after the formation of DSBs (as shown), or before the initiation of DSBs. Third, the DNA ends are aberrantly repaired, probably by alternative non-homologous end-joining (NHEJ). DNA junctions frequently show short stretches of homology that are referred to as microhomology and are indicated in the figure by the asterisk. In the final step, expression of the fusion gene confers a growth and/or survival advantage, which enables clonal selection and expansion. b | The boxes in the figure provide a summary of the different types of chromosomal rearrangements that lead to oncogenic tyrosine kinase fusions. Interchromosomal rearrangements, principally reciprocal translocations, are the most common type (left). However, intrachromosomal rearrangements (right), which include paracentric inversions, intrachromosomal deletion or tandem duplication, are also observed. All known anaplastic lymphoma kinase (ALK) and ROS1 fusions are shown here by the type of chromosomal rearrangement. Of note, complex rearrangements (not shown in the figure) may also lead to tyrosine kinase fusion genes. C2orf44, chromosome 2 open reading frame 44; CCDC6, coiled-coil domain-containing 6; CSR, class switch recombination; EML4, echinoderm microtubule-associated protein-like 4; EZR, villin 2; FIG, fused in glioblastoma; KDELR2, KDEL endoplasmic reticulum protein retention receptor 2; KIF5B, kinesin family member 5B; KLC1, kinesin light chain 1; LRIG3, leucine rich repeats and immunoglobulin-like domains 3; SDC4, syndecan 4; SLC34A2, solute carrier family 34 member 2; STRN, striatin; TFG, TRK-fused gene; TPM, tropomysin; VCL, vinculin; VDJ, variable diverse joining.
morphologies that may facilitate specific gene rearrangements; for example, RET and one of its fusion partners, coiled-coil domain-containing 6 (CCDC6), were shown to be juxtaposed (in close proximity to each other) in the nucleus in 35% of normal thyroid cells but only 6% of normal mammary epithelial cells 52 . The low frequency of RET-CCDC6 juxtaposition in breast epithelial cells may explain the absence of this rearrangement in human breast cancers. Indeed, recent work has provided genome-wide evidence that the rearrangement frequency is related to the contact frequency 53, 54 . Nevertheless, biological selection for translocations in specific cell types is also thought to have an important role in the development of cancer; for example, in normal lymphocytes, RET and CCDC6 colocalize in the nucleus to a similar extent as in thyroid cells 52 , which implies that the occurrence of RET-CCDC6 fusion is equally probable in thyroid cells and lymphocytes. However, transgenic mice that have a RET-CCDC6 fusion develop thyroid tumours and not lymphomas, and RET-CCDC6 fusions have not been found in human lymphomas. These findings suggest that the oncogenicity of tyrosine kinase gene fusions may be influenced by the cellular context.
The importance of selection is also shown in a recent study of 14 breast cancer cell lines in which 77 gene fusion events were identified, 62% of which were localized to amplicons 55 . Many of the gene fusions were recurrent or involved known, highly expressed oncogenic drivers. Closer examination of two separate recurrent gene fusions that involved ribosomal protein S6 kinase β1 (RPS6KB1; a serine/threonine kinase downstream of mTOR) and the epidermal growth factor receptor (EGFR; a receptor tyrosine kinase) showed that cells that harbour these fusions were not addicted to signalling by the rearranged kinases. Of note, both gene fusions represented a minor allelic fraction of the amplified locus, the kinase domains of RPS6KB1 and EGFR were absent from the fusions and the wild-type (or non-rearranged) kinases were still expressed. Thus, certain fusions -in particular, those associated with amplifications -may not represent clonally selected events and may simply be by-products or 'passengers' in the setting of considerable chromosomal disarray.
The biology of oncogenic fusion kinases
The tyrosine kinase fusions in epithelial cancers result from various types of chromosomal rearrangements, all of which lead to the fusion and aberrant activation of a tyrosine kinase (FIG. 1b) . One of the most common types of rearrangement is interchromosomal translocation, which involves the exchange of chromosomal material between heterologous chromosomes. Intrachromosomal rearrangements are also common, particularly paracentric inversions, which do not include the centromere. As an example, echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusions in lung cancer are the result of paracentric inversions that involve the short arm of chromosome 2 (REF. 3). Pericentric inversions seem to be much less common; only one tyrosine kinase fusion -the kinesin family member 5B (KIF5B)-RET fusion in lung cancer -occurs as a result of a pericentric inversion in the centromeric region of chromosome 10 (REFS 56, 57 (FIG. 1b) .
Although the type of chromosomal rearrangement may differ, several common features define tyrosine kinase fusions in cancer. First, the portion of the tyrosine kinase gene that is involved in the fusion encodes the intact kinase domain, which includes a GXGXXG motif that is highly conserved across all the fusions and is essential for activity 59 (FIG. 2) . Second, for each tyrosine kinase the breakpoint is often conserved across the various fusions; for example, for ALK the breakpoint is found in intron 20 across most of the fusions in lung cancer and other tumour types [60] [61] [62] . In addition, breakpoints usually occur within one of the three introns that are located 5ʹ to the GXGXXG-encoding exon 59 (FIG. 2) . Third, each tyrosine kinase often has numerous fusion partners, even in the same disease (TABLE 1) ; for example, in papillary thyroid cancer there are more than ten known RET partners. Different portions of a partner gene may be fused to the tyrosine kinase, which generates additional 'variants' and further complicates the situation. In ALKrearranged lung cancer, there are five known partners -EML4, TRK-fused gene (TFG), KIF5B, kinesin light chain 1 (KLC1) and striatin (STRN) -that constitute approximately 30 different fusion variants, 22 of which are EML4-ALK variants 62, 63 . Despite the diversity of fusion partners, tyrosine kinase fusions typically share a common mechanism of kinase activation. Most fusion partners contain coiledcoil or leucine zipper domains that drive the dimerization or oligomerization of the fusion kinase, which leads to ligand-independent activation of the tyrosine kinase. Almost all ALK and RET fusion partners contribute one or more coiled-coil domains to their respective kinase fusions. Other dimerization motifs that may have an important role in kinase activation include sterile alpha motif (SAM), LisH and BAR domains, which have been recently observed in fibroblast growth factor receptor 1 (FGFR1) fusions [64] [65] [66] [67] . Although oligomerization of the fusion kinase seems to be the dominant mechanism of tyrosine kinase activation, several other mechanisms have also been reported; for example, rather than providing dimerization motifs, fusion partners can provide 5ʹ regulatory sequences that drive high-level expression and activation of tyrosine kinases. For ALK fusions, the endogenous ALK gene is normally not expressed in most adult tissues, including the lung epithelium, but rearrangement leads to both ectopic expression and constitutive activation of the ALK fusion protein. Kinase cancer and SR-related C-terminal domain-associated factor 11 (SCAF11)-platelet-derived growth factor receptor-α (PDGFRA) in lung adenocarcinoma 64, 68 . In the case of the SLC45A3-FGFR2 fusion, the noncoding first exon of SLC45A3 is fused to the entire coding region of FGFR2, which results in considerable overexpression of the native tyrosine kinase. Other possible mechanisms of tyrosine kinase activation include increased expression resulting from loss of microRNA regulation, and conformational changes that favour the activated state 69, 70 . Interestingly, in contrast to ALK, RET and FGFR1-FGFR3, ROS1 fusion partners frequently do not contain coiled-coil or other dimerization domains 8 . It remains unknown whether any of these alternative mechanisms lead to the activation of ROS1 and other fusion kinases that lack dimerization domains.
Numerous studies have shown that the catalytic activity of tyrosine kinase is essential for the transforming capacity of fusion kinases. However, other factors -such as altered subcellular localization -may also be important. Rearrangements of ALK result in loss of the ALK transmembrane domain, which leads to re-localization from the plasma membrane to the cytoplasm. Most RET fusions also lack the RET transmembrane domain, but depending on the particular fusion partner they may still reside in the plasma membrane (as occurs with nuclear receptor coactivator 4 (NCOA4)-RET) 71 or relocate to different cytoplasmic compartments 7 . Such changes in subcellular localization may lead to interaction with different substrates and/or differential engagement of downstream signalling pathways that are important for cellular transformation. Changes in subcellular localization may also lead to other sequelae, as suggested by studies of FGFR3-TACC3 (transforming acidic coiled-coil-containing protein 3) in glioblastoma. Mislocalization of this fusion kinase to mitotic spindle poles causes defects in mitotic and chromosomal segregation, which lead to aneuploidy 72 . In this case, the induction of aneuploidy may cooperate with constitutive kinase activity to drive tumorigenesis.
The role of tyrosine kinase fusions as oncogenic drivers has been well established in preclinical models, which include transgenic mouse models of kinase fusion-driven cancers. In these models, aberrant activation of downstream signalling pathways promotes crucial aspects of the malignant phenotype, which include uncontrolled cellular proliferation and survival. A full discussion of the signalling networks that are activated by each tyrosine kinase fusion is beyond the scope of this Review. However, one key feature that is common to cancers harbouring many kinase fusions is the dependency of the cancer on continued signalling from the oncogenic kinase for cell growth and survival. This dependency has been termed oncogene addiction, and various hypotheses have been proposed to explain its mechanistic basis 73, 74 . In one model, the regulation of key downstream signalling pathways, such as canonical Regions that encode the transmembrane and kinase domains (as designated in UniProt) are shaded in blue and green, respectively, and were mapped using MapBack. The exon that encodes the GXGXXG motif is indicated with an asterisk. The isoform depicted for each kinase corresponds to the canonical isoform that is designated in UniProt unless a non-canonical isoform (for example, neurotrophic tyrosine kinase receptor type 3 (NTRK3)) or multiple isoforms (for example, fibroblast growth factor receptor 2 (FGFR2) and FGFR3 (alternative exon 7, isoform number in superscript)) were specifically indicated in the primary reference. ALK, anaplastic lymphoma kinase; PDGFRA, platelet-derived growth factor receptor-α.
MEK-ERK and PI3K-AKT pathways, is strictly controlled by the activated tyrosine kinase (for example, ALK or ROS1) 75 . Inhibition of the oncogenic kinase, by the knockdown of short hairpin RNA (shRNA) or by smallmolecule tyrosine kinase inhibitors, suppresses these signalling pathways, which results in growth arrest and apoptotic cell death. In several cancers that are addicted to tyrosine kinases, such as ALK-rearranged lung cancer, the suppression of the MEK-ERK and PI3K-AKT pathways alters the expression levels of BCL-2 family members, leading to apop tosis. For example, suppression of the MEK pathway leads to induction of the pro-apoptotic protein BIM (also known as BCL2L11) [76] [77] [78] [79] [80] [81] [82] , and suppression of the PI3K-AKT pathway leads to either upregulation of the pro-apoptotic protein PUMA or suppression of the anti-apoptotic protein MCL1 depending on the particular type of cancer 83, 84 . Concurrent changes are required in the expression of multiple BCL-2 family members by the suppression of both MEK-ERK and PI3K-AKT pathways to promote apoptosis. In the clinic, the induction of apoptosis seems integral to tumour response, because cancers with deficient BIM expression had worse clinical outcomes when treated with tyrosine kinase inhibitors 81, 85 .
Therapeutic strategies for fusion kinases
The phenomenon of oncogene addiction underlies the considerable antitumour activity of small-molecule tyrosine kinase inhibitors in cancers that harbour tyrosine kinase fusions. Several of these tyrosine kinase inhibitors have already shown great promise in the clinic and, in the case of lung cancers with ALK rearrangements, have become the standard of care. An alternative strategy for targeting tyrosine kinase fusions is the inhibition of heat shock protein 90 (HSP90), which is a molecular chaperone that is required for proper folding and stabilization of various oncogenic proteins, including kinase fusions. Below, we review the clinical results obtained from the use of these therapeutic approaches for epithelial cancers that harbour chromosomal rearrangements.
ALK inhibitors.
Crizotinib was the first small-molecule tyrosine kinase inhibitor of ALK that was tested in the clinic 86 . Originally developed to target the receptor tyrosine kinase MET, crizotinib was subsequently found to inhibit several other kinases, including ALK and ROS1 (as discussed below) 87, 88 . In cell-based autophosphorylation assays, crizotinib was shown to be a potent inhibitor of both MET and ALK, with a half-maximal inhibitory concentration (IC 50 ) of 8 nM and 20 nM, respectively 89 . In cell lines that expressed ALK fusions, the use of crizotinib resulted in decreased levels of phosphorylated ALK and the suppression of downstream signalling pathways, which led to inhibition of cell proliferation and induction of apoptosis. Crizotinib also showed potent antitumour activity in various different human xenograft models, which included a lymphoma model that expressed the nucleophosmin (NPM)-ALK fusion and lung cancer models that harboured the EML4-ALK fusion 88, 90, 91 . Consistent with the preclinical data, crizotinib has shown significant clinical activity in patients with advanced, ALK-rearranged NSCLC. During Phase I and Phase II clinical trials of crizotinib, the objective response rate (the percentage of patients with a ≥30% reduction in tumour size) was approximately 60% 92, 93 . Responses were often rapid and durable; the estimated median response duration was 49.1 weeks in the Phase I study 92 . Results from the first Phase III randomized study of crizotinib were recently reported 94 . In this study, patients with advanced ALK-rearranged NSCLC were randomized to receive either crizotinib or standard chemotherapy as their second-line treatment. Compared to chemotherapy, the use of crizotinib resulted in an increased progression-free survival (PFS; 7.7 months versus 3 months), improved the response rate (65% compared with 19%) and improved both disease-related symptoms and quality of life. In a preliminary analysis, no difference in overall survival was seen; however, this survival analysis was probably confounded by the crossover of patients from chemotherapy to crizotinib. Furthermore, across all studies to date, the side effects of crizotinib have generally been mild and manageable, probably reflecting the limited expression of ALK in normal adult tissues. On the basis of its safety and efficacy, crizotinib was granted accelerated approval by the US Food and Drug Administration (FDA) in August 2011, just 4 years after the discovery of ALK rearrangements in NSCLC 3 . Results from the Phase III study have established this ALK inhibitor as a standard therapy for patients with advanced ALK-rearranged NSCLC.
The successful targeting of ALK in lung cancer has spurred the development of numerous next-generation ALK inhibitors (TABLE 2) . In general, these new ALK inhibitors are more potent and selective than crizotinib; for example, CH5424802 was identified in a highthroughput screen for inhibitors of ALK 95 . In cell-free enzymatic assays, CH5424802 was highly potent against ALK; it had an IC 50 of 1.9 nM. CH5424802 was also more selective than crizotinib, and it showed little or no inhibitory activity against other kinases, which included MET and ROS1 (REFS 95, 96) . In a Phase I and Phase II study that recruited patients from Japan, CH5424802 was shown to be associated with a response rate of 93.5% in crizotinib-naive, ALK-rearranged NSCLC 97 . Whether this remarkably high response rate was because of the increased potency of CH542802 compared with that of crizotinib is uncertain. Other factors that might have contributed to the high response rate include more rigorous diagnostic screening for ALK rearrangements (BOX 2) and higher drug exposures because of the Asian ethnicity of the study population 98 . Nevertheless, the clinical efficacy of this highly selective ALK inhibitor confirms a singular role for ALK in mediating oncogene addiction in ALK-rearranged lung cancer.
In addition to increased potency and selectivity, next-generation ALK inhibitors have variable activity against mutant forms of ALK that are resistant to crizotinib. Therefore, several new inhibitors are specifically being tested in patients who have relapsed while receiving crizotinib therapy. To date, preliminary results have been reported for two of the next-generation ALK inhibitors -AP26113 and LDK378 (TABLE 2) . A Phase I study of AP26113 showed that the preliminary response rate among patients with crizotinib-resistant disease was 75% (12 out of 16 patients) 99 . Similarly, LDK378 has been associated with a high response rate (near 60%) in crizotinib-resistant, ALK-rearranged NSCLC, and with a prolonged median PFS 100 . The clinical activity of nextgeneration ALK inhibitors is noteworthy because only one-third of crizotinib-resistant patients have resistance mutations within the tyrosine kinase domain of ALK 82, 101, 102 . The ability of next-generation ALK inhibitors to overcome resistance in most patients suggests that most crizotinib-resistant tumours remain ALKdependent and that subtherapeutic inhibition of the tyrosine kinase fusion may be an important factor that contributes to crizotinib resistance.
ROS1 inhibitors.
ALK inhibitors have also shown activity against ROS1 fusions in several different experimental systems; for example, in a screen that involved more than 600 cancer cell lines, ten lines showed a considerable sensitivity to the ALK inhibitor TAE684. Although eight out of these ten sensitive cell lines were known to harbour a genetic abnormality of ALK, such as ALK rearrangement, one out of the ten cell lines was a lung cancer cell line that harboured the SLC34A2-ROS1 fusion 4, 90 . In preclinical studies ROS1 was subsequently shown to be a target of crizotinib. In cell-based autophosphorylation assays, crizotinib was a potent inhibitor of both ALK and ROS1 to similar extents 103 . In addition, in cell line models that expressed the CD74-ROS1 fusion, crizotinib inhibited cell growth and suppressed phosphorylation of ROS1, which led to downregulation of downstream signalling pathways 10, 103 . As shown in TABLE 2, most ALK inhibitors are also ROS1 inhibitors, with the exception of CH5424802. The molecular basis for this dual inhibition is straightforward. Although ROS1 is a distinct receptor tyrosine kinase, it is closely related to ALK and to the insulin receptor family of tyrosine kinases 104 . At the amino acid level, the tyrosine kinase domains of ALK and ROS1 are very similar -the domains have 77% identity within the ATP-binding sites. On the basis of computational modelling of the tyrosine kinase domains of ALK and ROS1 bound to crizotinib, most of the amino acid differences are not predicted to significantly affect crizotinib binding. The exception to this is a Val-to-Leu change at codon 1194, which does make direct contact with crizotinib 103 . However, overall the ROS1 binding site seems to be nearly identical to that of ALK, and this observation probably explains the inhibition of ROS1 by crizotinib and other ALK inhibitors.
In the clinic, crizotinib has shown significant activity in ROS1-rearranged NSCLC, which is reminiscent of its activity in ALK-rearranged NSCLC. In the ongoing Phase I study of crizotinib, the response rate among patients with advanced ROS1-rearranged NSCLC was 60% (21 out of 35 patients). The median PFS has not been reached, but the probability of a continued response at 6 months was 76% 105 . On the basis of these findings, a pivotal trial of crizotinib in advanced ROS1-rearranged NSCLC is being planned in Asia, and we anticipate that crizotinib will probably become a standard treatment for this molecular subtype of lung cancer. Whether crizotinib has clinical activity in other ROS1-rearranged cancers, such as cholangiocarcinoma and gastric cancer, is unknown. The potential role of next-generation ALK inhibitors with ROS1 activity in ROS1-rearranged cancers is also unknown. As there may be common resistance mechanisms in ALK-rearranged and ROS1-rearranged NSCLC 96 , inhibitors that have more potent ROS1 activity than crizotinib may represent a therapeutic strategy to overcome resistance. a b RET inhibitors. RET has long been recognized as a potential oncogenic driver in human cancer. RET is frequently activated by mutations in medullary thyroid cancer, in both familial and sporadic cases, and by chromosomal rearrangement in papillary thyroid cancer (TABLE 1) . Although most differentiated thyroid cancers, such as papillary thyroid cancers, are potentially curable -using surgery, radioactive iodine and thyroid hormone therapy -medullary thyroid cancers have a lower cure rate. For patients with unresectable or metastatic medullary thyroid cancer, the multi-targeted tyrosine kinase inhibitors vandetanib and cabozantinib have been approved by the FDA on the basis of improvements in PFS (relative to the PFS with placebo) 106, 107 . Both of these agents inhibit RET and various other tyrosine kinases including vascular endothelial growth factor receptor 1. Other multikinase inhibitors with anti-RET activity, such as sunitinib and sorafenib, have also shown promising results in the treatment of medullary thyroid cancer. However, several inhibitors that do not have substantial anti-RET activity have been associated with tumour responses in both medullary and papillary thyroid carcinoma, which suggests that there are important roles for kinases other than RET that may be inhibited by these multikinase inhibitors. Interestingly, although RET rearrangements typically occur in one-third of papillary thyroid cancers, they were not identified in patients with advanced disease in two trials that carried out tumour genotyping 108, 109 , which suggests that RET-rearranged papillary thyroid cancer has a more indolent disease phenotype.
Preclinical and early clinical studies suggest that RET may be a bona fide therapeutic target in NSCLC. Several different RET fusions have been identified (TABLE 1) and demonstrate oncogenic activity in vitro and in vivo. In preclinical models, tyrosine kinase inhibitors that target RET decrease the viability of cancer cells that are Box 2 | Diagnostic assays that are used in the clinic to identify recurrent chromosomal rearrangements Several diagnostic tests are currently used in the clinic to identify recurrent chromosomal rearrangements in solid tumours. These diagnostic assays are crucially important, as they identify those patients who will probably benefit from a targeted therapy. The most common diagnostic test is a break-apart fluorescence in situ hybridization (FISH) assay. This assay consists of two differently coloured fluorescent probes that hybridize to sequences on either side of the translocation breakpoint. In the presence of a chromosomal rearrangement, the probes are spatially separated, which creates a visual splitting of the two colours (see white arrows in the figure, panel a) . On occasion, a chromosomal rearrangement can also be indicated by loss of the 5ʹ probe and the presence of an isolated 3ʹ signal. By contrast, the native or non-rearranged chromosome is typically observed as a fused signal. An anaplastic lymphoma kinase (ALK) FISH diagnostic assay was used in the Phase I and Phase II trials of crizotinib, the results of which led to accelerated approval of this drug in the United States 86 ; indeed, ALK FISH is currently the gold standard in the United States and the only US Food and Drug Administration-approved diagnostic test for the detection of ALK rearrangements. Similar break-apart FISH assays have also been used in early-phase studies of ROS1-rearranged and RET-rearranged lung cancers 10, 110 . As FISH requires specialized resources and considerable expertise, other diagnostic tests for chromosomal rearrangements have been developed. In the case of ALK-rearranged non-small-cell lung cancer (NSCLC), immunohistochemistry (IHC) will probably replace FISH as the diagnostic test of choice because of its wider availability and affordability. IHC is particularly suitable for ALK-rearranged NSCLC because the expression of ALK is extremely limited in adulthood and only occurs in the lung following a chromosomal rearrangement. Several ALK-specific antibodies are available and show high sensitivity and specificity for detecting ALK expression (see the figure, panel b) . In the Phase I study of a next-generation ALK inhibitor, CH5424802, ALK IHC was used to screen patients and ALK FISH was used for confirmation. In Europe, an IHC companion diagnostic is already available, which uses the rabbit monoclonal ALK antibody D5F3 (REF. 127 ). IHC might also be used in the detection of ROS1 rearrangements; in a panel of over 500 lung tumours, IHC -using the ROS1 D4D6 rabbit monoclonal antibody -identified nine cases with ROS1 rearrangement, eight of which were confirmed by ROS1 FISH 128 . Larger validation studies are required before ROS1 IHC is adopted into routine practice. As next-generation sequencing technologies continue to improve, single-gene assays such as FISH and IHC are unlikely to remain the standard diagnostic tests for chromosomal rearrangements. Instead, targeted sequencing of all known oncogenic drivers, including those involved in chromosomal rearrangements, will probably become a standard part of the diagnostic work-up for all patients with advanced cancer.
transformed by the KIF5B-RET fusion protein 8, 56 . On the basis of these findings, several RET inhibitors are now used in clinical trials for RET-rearranged lung cancers (TABLE 3) . Preliminary efficacy data have recently been reported for the use of cabozantinib in advanced, RET-rearranged NSCLC 110 . Among three patients who were treated with cabozantinib, two of the patients achieved a confirmed response and the remaining patient demonstrated disease stabilization for more than 31 weeks. In a separate case report, vandetanib induced a favourable response in a patient with RET-rearranged NSCLC 111 . Although the data are limited, these initial cases suggest that RET rearrangement defines another oncogene addiction paradigm in NSCLC.
FGFR inhibitors. FGFR family members can be activated by point mutations, gene amplifications or chromosomal rearrangements. Since the first reports of FGFR1 and FGFR3 fusions in haematological malignancies 112, 113 , various oncogenic FGFR fusions have been discovered in solid tumours, which include glioblastoma and several epithelial cancers 64, 68, 72 (TABLE 1) . In both cell line and xenograft experiments, FGFR fusion kinases confer sensitivity to small-molecule FGFR inhibitors such as PD173074 and pazopanib 64 . Bladder cancer cell lines that have FGFR3 fusions seem to be more sensitive to FGFR inhibitors than cell lines that have activating FGFR3 mutations 64, 114 . Furthermore, in FGFR3-TACC3-transformed Rat1A fibroblasts, treatment using PD173074 not only inhibits cell growth but also reduces the chromosomal instability and aneuploidy that is triggered by the expression of the tyrosine kinase fusion 72 .
To date, there are no reported data on the clinical efficacy of FGFR inhibitors in patients with FGFRrearranged cancers. However, several FGFR inhibitors are currently in clinical development for patients with tumours that harbour genetic alterations of FGFR, which include chromosomal rearrangements (TABLE 4) . HSP90 inhibitors. HSP90 is a highly conserved molecular chaperone that has an important role in the proper folding, stabilization and activation of numerous client proteins 115 . Several tyrosine kinase fusions are HSP90 clients, including BCR-ABL and EML4-ALK. As fusion proteins may be inherently less stable than native proteins, HSP90 inhibition might be a general strategy for treating kinase fusion-driven cancers.
ALK fusions were first identified as novel HSP90 clients in anaplastic large-cell lymphoma cells that expressed NPM-ALK. The association of NPM-ALK with HSP90 was disrupted by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), which led to the destabilization and degradation of the fusion protein, decreased kinase activation and decreased downstream signalling 116 . Similarly, in lung cancer, EML4-ALK has also been shown to be an HSP90 client. The sensitivity of this ALK fusion to HSP90 inhibitors was first observed in a clinical trial of retaspimycin hydrochloride (IPI-504) in patients with advanced NSCLC 117 . Several different HSP90 inhibitors -17-AAG, 17-DMAG (17-(demethoxy),17-dimethylaminoethylamino geldanamycin), ganetespib and AUY922 -have shown activity in cell line, xenograft and genetically engineered mouse models of ALKrearranged lung cancer 91, [117] [118] [119] [120] . The degree of sensitivity to HSP90 inhibition may depend upon the particular fusion; for example, in Ba/F3 cells, EML4-ALK variants 1 and 2 were found to be sensitive to 17-DMAG, whereas EML4-ALK variant 3 was relatively resistant to this inhibitor 119 . In addition to ALK fusions, ROS1 and RET fusions are HSP90 client proteins. In immunoprecipitation experiments, CCDC6-RET fusion is associated with HSP90 and its co-chaperone CDC37 (also known as p50). Treatment of a CCDC6-RET-expressing thyroid cell line with 17-AAG leads to a reduction in the levels of the fusion protein 121 . Ganetespib has also recently been shown to inhibit the viability of the same RETrearranged cell line by leading to a dose-dependent destabilization of the fusion, a decrease in MAPK signalling and induction of apoptosis 120 . Ganetespib is also active in various models of ROS1-rearranged cancers, including the lung cancer cell line HCC78, which harbours the SLC34A2-ROS1 fusion 120 . Whether different ROS1 and RET fusions have differential sensitivity to HSP90 inhibitors is not yet known.
Among the 20 HSP90 inhibitors that are currently in clinical development, three ongoing studies include molecularly defined cohorts of patients with advanced cancers that harbour tyrosine kinase rearrangements (see Supplementary information S1 (table)). To date, the results are limited, with small numbers of patients in each trial. IPI-504 use was associated with responses in two out of three patients who had advanced, ALKrearranged NSCLC. All three cases were crizotinib-naive, and each patient received IPI-504 for approximately 7 months 117 . High response rates have also been reported with ganetespib and AUY922 in crizotinib-naive, ALKrearranged NSCLC; four out of eight responses were observed using each HSP90 inhibitor 122, 123 . For AUY922, the PFS rate at 18 weeks was 62.5% 123 , which suggested that there may be a moderate duration of response. The clinical activity of HSP90 inhibitors in other tyrosine kinase fusion-driven epithelial cancers has not yet been reported.
Although only preliminary data are available at present, we speculate that single-agent HSP90 inhibitors will probably not be superior to tyrosine kinase inhibitors in treatment-naive patients, in part because of their relatively narrow therapeutic index. However, there are two specific clinical settings in which HSP90 inhibitors may have potential uses. First, patients invariably develop resistance to targeted therapies such as crizotinib, which typically occurs after 1 year of treatment. As HSP90 inhibition affects not only the fusion kinase but also other client proteins, some of which may mediate resistance, HSP90 inhibitors may be effective in patients -especially those with ALK resistance mutations -who have relapsed while receiving tyrosine kinase inhibitors. In preclinical studies, HSP90 inhibitors have shown potent activity in models of crizotinibresistant, ALK-rearranged NSCLC that harbours ALK resistance mutations 82, 91, 120 . In the clinic, responses have been observed in a handful of crizotinib-resistant cases: in a single patient who was treated with ganetespib 120 , and in 3 out of 11 patients (27%) who were treated with AUY922 (REF. 123 ). Second, in either treatment-naive or resistant settings, HSP90 inhibitors may be more useful in combination with tyrosine kinase inhibitors than as . Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions were discovered more than 20 years later by using a similar transformation assay in which mouse 3T3 fibroblasts were infected with a retroviral cDNA expression library that was prepared using the lung adenocarcinoma sample from a patient 3 . At around the same time, a phosphoproteomics-based strategy was used to define the profile of activated tyrosine kinases across multiple non-small-cell lung cancer (NSCLC) samples 4 . Novel candidate driver kinases were identified using this analysis, including ALK, ROS1, platelet-derived growth factor receptor-α (PDGFRα) and epithelial discoidin domain-containing receptor 1 (DDR1). Using this same method, in-frame rearrangements between ROS1 and the fused in glioblastoma (FIG) gene were subsequently discovered in cholangiocarcinoma 129 . Using breakpoint analysis of exon array data, EML4-ALK fusion transcripts were discovered not only in NSCLC but also in breast and colorectal cancer samples 130 . Exon arrays were also used to identify a RET-CCDC6 (coiled-coil domain-containing 6) fusion in a patient with lung cancer without any other known oncogenic drivers 131 . The same RET-CCDC6 fusion had been previously discovered in papillary thyroid cancer 25 years before the exon array study by using an NIH3T3 transformation assay 132 . Existing exon array and comparative genomic hybridization (CGH) data sets have most recently been mined to identify rearrangements, such as CEP85L-ROS1 in angiosarcoma 133 . In addition, systematic analyses of large-scale cancer tissue microarrays with immunohistochemistry and fluorescence in situ hybridization (FISH) have shown novel kinase fusions in different cancer types.
Next-generation sequencing approaches. Whole-transcriptome or RNA sequencing is currently the predominant method used to identify novel kinase rearrangements. Indeed, this method was used to identify the first RET rearrangement, kinesin family member 5B (KIF5B)-RET, in lung adenocarcinoma 57, 134 . An assortment of fibroblast growth factor receptor (FGFR) fusions has recently been identified in various solid tumours 64 , which include cholangiocarcinoma, squamous cell lung cancer, bladder cancer and others (TABLE 1) . Focused kinome-centered RNA sequencing methods have identified a recurrent FGFR3-TACC3 (transforming acidic coiled-coil-containing protein 3) fusion in squamous cell lung cancer, as well as a previously unidentified ALK fusion, striatin (STRN)-ALK, in a lung adenocarcinoma 69 . Although transcriptome sequencing is relatively fast and allows for verification of active expression, it may fail to detect rearrangements that occur within non-coding DNA.
Genome sequencing is the most comprehensive method that can be used to identify novel rearrangements, although an enrichment step is usually used to focus analyses on the sequences of interest. ALK and RET rearrangements, for example, have been identified by next-generation genomic DNA sequencing of colorectal and NSCLC samples 56 . Two previously unidentified neurotrophic tyrosine kinase receptor type 1 (NTRK1) gene rearrangements in NSCLC samples that lacked identifiable oncogenic drivers have also been discovered using this method 135 . A technique has been developed that takes advantage of the fact that most tyrosine kinase breakpoints in cancer occur within 200 amino acids upstream of conserved GXGXXG kinase motifs 59 . In a leukaemia patient with no known gene rearrangements, this technique was used to identify a novel CEP85L-PDGFRB fusion 136 . As cancers continue to be investigated using whole-genome and transcriptome sequencing methods, it is likely that additional kinase fusions will be discovered.
single agents. Such combinations would enable targeting of the fusion kinase in two different ways, and allow the inhibition of potential mediators of resistance. In treatment-naive patients, the dual inhibition of the fusion kinase could potentially suppress the outgrowth of clones with secondary kinase resistance mutations. Three Phase I studies are now investigating the effects of combining HSP90 inhibitors with ALK tyrosine kinase inhibitors in advanced, ALK-rearranged NSCLC (see Supplementary information S1 (table)).
Conclusions and future directions
The recent discovery of tyrosine kinase fusion events in epithelial malignancies has not only affected the molecular classification and treatment of solid tumours but also revealed new challenges in the field. Although numerous fusion kinases have already been identified, there are probably more to be discovered, and emerging nextgeneration sequencing technologies will probably facilitate these breakthroughs
. As tyrosine kinase gene rearrangements generally define rare subsets of patients with common cancers (TABLE 1) , the identification of suitable patients for clinical trials that test specific targeted therapies will require prospective screening of a large number of patients. This screening will potentially need to include different tumour types. Multiplexed genetic ana lyses that include screening for fusion kinases will be crucial to expediting the process of target discovery and clinical validation. However, the financial costs of widespread and comprehensive genotyping will need to be addressed, in particular when no clinical benefit has yet been shown.
As discussed in this Review, the aetiology of chromosomal rearrangements in epithelial cancers is poorly understood. Elucidation of the molecular mechanisms that lead to these rearrangements may help to identify risk factors that can be modified or other preventive methods that can reduce the incidence of these malignancies. In addition to the oncogenic fusions that involve tyrosine kinases, rearrangements can activate other types of kinases (BOX 1) as well as non-kinase oncogenes such as transcription factors. Given the large number of kinase inhibitors that are already available, as well as the potential to drug even 'undruggable' targets, it is probable that therapies targeting other oncogenic fusions will also affect the diagnosis and treatment of some epithelial cancers.
